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Ninety-eight postnatal and six prenatal cases of thalassemia were studied by the reverse dot-blot 
hybridization technique in the city of Gaziantep, Turkey. We found the following mutations: IVS 1.110 
(G>A) in 29.1%, IVS 2.1 (G>A) in 12.3%, IVS 1.1 (G>A) in 7.7%, Codon 8 (−AA) in 5.6%, -30 (T>A) in 4.6%, 
IVS 1.6 (T>C) in 4.6%, Codon 39 (C>T) in 3.6%, Codon 44 (-C) in 3.1%, IVS 2.745 (C>G) in 1.5%, Codon 8/9 
(+G) in 2.1%, Codon 36/37 (-T) in 2.1%, IVS 1.5 (G>C) in 2.1%, Codon 22 (7pb del) in 0.5%, Codon 5 (-CT) 
in 0.5% while 20.9% were undetermined. 54 of the thalassemia patients were homozygotes, 12 were 
compound heterozygous and 31 were heterozygotes. In one allele of 5 thalassemia patients, -
thalassemia mutation (3.7 single gene deletions in 1 patient, anti-3.7 gene triplication in 4 patients) was 
determined at the same time. Finally, this is the first comprehensive study in this region and percentage 
of  and - globin genes mutation is 2.6 and 79.4%, respectively. 
 





–Thalassemia (OMIM 141900) is one of the most 
common single gene defects in the world and it results 
from decrease in lack of -globin chain production. It is 
common in the Mediterranean, Middle East, Africa, India, 
South Asia and South China (Kuliev, 1988; Birgens and 
Ljung, 2007). In 0-thalassemia, there is no production of 
the -globin chain and is an important cause of morbidity 
and mortality being associated with severe hypochromic 
hemolytic anemia, the requirement of frequent blood 
transfusions and lifetime iron-chelating treatment; in +-
thalassemia, the -globin chain is produced to a lesser 
extent than normal (Kuliev, 1988; Borgna-Pignatti and 
Galanello, 2003).  
-Thalassemia (OMIM 141800) is the most common 
inherited disorder of hemoglobin (Hb) synthesis in the 
world, with gene frequencies varying between 1 and 98% 
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ethnic groups but is more common in those of Southeast 
Asian descent. The American College of Obstetricians 
and Gynecologists recommends hemoglobinopathy 
screening for those of African, Southeast Asian and 
Mediterranean descent. More than 95% cases of recog-
nized -thalassemia involve deletion of one or both -
globin genes from chromosome 16p13.3 (www.labcorp. 
com/datasets 6300.htm - 05.08.2009). 
The number of affected births is higher than expected 
in Turkey because of a large and young families that 
have many children and the number of consanguineous 
marriages especially first cousins are above 60% in the 
Eastern and Southern parts of Turkey (Basak, 2008). 
Genetic counseling and prenatal diagnosis programs play 
an important role in overcoming the problem.  
We have aimed the frequency  and -thalassemia 
mutations among 98 patients and 6 prenatal cases.  
 
 
MATERIALS AND METHODS 
 
We looked for  and -thalassemia mutations in 196 chromosomes 
of 98 thalassemia patients (52 male, 46 female) between  the  ages  
 
 




Table 1. Frequency of -thalassemia mutations (%) in Turkey. 
 
Mutation Gaziantep Cukurova Diyarbakir Aegean Denizli Turkey 
IVS 1.110 (G>A) 29.1 57.3 27.8 44.1 36.4 39.2 
IVS 2.1 (G>A) 12.3 3.4 8.3 2.7 3.6 5.4 
IVS 1.1 (G>A) 7.7 8.3 2.8 28.2 16.4 5.5 
Codon 8 (–AA) 5.6 4.7 11.1 - 3.6 6.1 
-30 (T>A) 4.6 5.7 2.8 - - 3.1 
IVS 1.6 (T>C) 4.6 5.7 11.1 13.3 7.3 9.5 
Codon 39 (C>T) 3.6 6.4 2.8 2.4 9.1 3.8 
Codon 44 (-C) 3.1 0.7 NS - - 1.3 
IVS 2.745 (C>G) 1.5 2.8 NS 9.3 7.3 4.6 
Codon 8/9 (+G) 2.1 0.4 3 - 1.8 1.5 
Codon 36/37 (-T) 2.1 0.7 1.2 - - <1 
IVS 1.5 (G>C) 2.1 0.4 NS - 1.8 1.1 
Codon 22 (7bp del) 0.5 - - - - - 
Codon 5 (-CT) 0.5 - - - - - 
Undetermined 20.9 ? ? ? ? ? 
Reference  11 12 14 13 5 




Table 2. Thalassemia patients who carry both  and -globin gene mutations.  
 
Patient Number Gender Age -globin gene mutation -globin gene mutation 
1 Female 1 heterozygote - IVS 2.1 (G>A) anti-3.7 gene triplication 
2 Female 27 Heterozygote - IVS 1.1 (G>A) anti-3.7 gene triplication 
3 Male 34 Homozygote - Codon 8 (–AA) anti-3.7 gene triplication 
4 Female 39 Homozygote - IVS 1.6 (T>C) anti-3.7 gene triplication 




of 1 and 52 years (mean: 15.1 ± 10.9 years) and 12 chromosomes 
of 6 fetuses whose parents’ mutations have been  known to have 
the -thalassemia trait. Hematological parameters were obtained 
with an automated cell counter. Consent from patients and family 
members were obtained before collection of blood and amniotic 
fluid samples. Genomic DNA was extracted from peripheral blood 
leukocyte using the salting out method techniques (Miller et al., 
1988). Fetus DNA was extracted from 3 ml amniotic fluid by using 
NucleoSpin Isolation Kit. Detection of known -globin gene muta-
tions was done using a commercialized reverse dot blot platform 
(Strip A ViennaLab. Diagnostics, Vienna, Austria) which included 
the following: IVS 1.110 (G>A), IVS 1.116 (T>G), IVS 2.1 (G>A), 
IVS 1.2 (T>A), IVS 1.1 (G>A), -30 (T>A), IVS 1.6 (T>C), Codon 39, 
Codon 44, Codon 22 , Codon 8/9, IVS 1.5 (G>C) , Codon 36/37, 
Codon 30, IVS 2.745 (C>G), IVS 1-25 (25bp del), -87 (C>G), 
Codon 5, Hemoglobin C (HbC), HbS, Codon 6 and Codon 8 
(Samara et al., 2007). Detection of known -globin gene mutations 
was done using a commercialized reverse dot blot platform (Strip B 
VienneLab. Diagnostics, Vienna, Austria) which included the 
following mutations: 3.7 single gene deletion (SGD), 4.2-SGD, MED 
double gene deletion (DGD), SEA-DGD, THAI-DGD, FIL-DGD, 20.5 
kb -DGD, anti-3.7 gene triplication, 1 cd 14 (TGG>TAG), 1 cd 59 
(GGC>GAC) (Hb Adana), 2 init cd (ATG>ACG), 2 cd 19 (–G), 2 
IVS1 (-5 nt), 2 cd 59 (GGC>GAC), 2 cd 125 (CTG>CCG) (Hb 
Quong Sze), 2 cd 142 (TAA>CAA) (Hb Constant Spring), 2 cd 
142 (TAA>AAA) (Hb Icaria), 2 cd 142 (TAA>TAT) (Hb Pakse), 2 
cd 142 (TAA>TCA) (Hb Koya Dora), 2 poly A-1 (AATAAA-
AATAAG) and 2 poly A-2 (AATAAA-AATGAA) (Hadavi et al., 
2007). Maternal contamination was eliminated using ChromoQuant 
version 2 kit (CyberGene AB, Sweden). 
 
 
RESULTS AND DISCUSSION 
 
The frequency of -thalassemia mutations is shown in 
Table 1. The ratio of + to o mutations was 0.58 (36/62). 
We detected 14 different mutations, of which six were 
present in 63.9% of the chromosomes. The IVS 1.110 
mutation, the most frequent mutation, was present in 
29.1% of all chromosomes. In Table 2, five thalassemia 
patients who carry both  and -globin gene mutation are 
summarized. Also we identified the ratio of the parents’ 
consanguinity is very high (49%). 
In Turkey, however a broad range of mutations had 
been observed, probably because of Turkey’s location at 
the three continents and of the influence of different 
cultures over the course of history. Although the muta-
tions that we identified in Gaziantep, were similar to those 
seen   elsewhere   in   our   country,   we  detected  some  
 
 




Table 3. Frequency of -thalassemia mutations in the Eastern Mediterranean. 
 
Mutation This study Turkey Cyprus Greece Syria Palestine Bulgaria Azerbaijan Iran Iraq 
IVS 1.110 (G>A) 29.1 39.3 79.7 42.1 24.1 17.6 24.2 20.2 4.8 1.9 
IVS 2.1 (G>A) 12.3 4.7 - 3.3 4.2 2.9 - - 33.9 18.3 
IVS 1.1 (G>A) 7.7 5.0 5.9 12.8 17.0 9 3.1 2.0 2.9 8.7 
Codon 8 (–AA) 5.6 5.5 0.2 0.8 0.7 - 5.5 21.2 4.5 2.9 
-30 (T>A) 4.6 3.1 - - - 2.1 - - - - 
IVS 1.6 (T>C) 4.6 10.1 6.2 8.1 4.2 28.7 10.2 7.1 1.1 8.7 
Codon 39 (C>T) 3.6 3.8 2.4 18.8 6.4 4.6 21.9 2.0 1.7 8.7 
Codon 44 (-C) 3.1 1.3  - 0.0 - - - 2.6 12.5 
IVS 2.745 (C>G) 1.5 5.0 5.5 6.3 - 0.3 6.9 3.1 - - 
Codon 8/9 (+G) 2.1 1.3 - - 1.4 1.4 0.3 2.0 4.8 7.7 
Codon 36/37 (-T) 2.1 0.1 - - - - - - - - 
IVS 1.5 (G>C) 2.1 1.1 - - 0.0 1.1 - - 7.6 6.7 
Codon 22 (7bp del) 0.5 0.1 - - 0.0 - - - 3.0 1.0 
Codon 5 (-CT) 0.5 - - - - - - -   




different frequencies between the regions (Table 1) (Cavdar 
and Arcasoy, 1971; Gurbak et al., 2006; Curuk et al., 
2001; Ince et al., 2003; Yildiz et al., 2005; Golesken et 
al., 2000). The IVS 2.1 (G>A) mutation is the second 
most frequent type (12.3%) in our study. This mutation 
occurs in 3.4% of the population in the Cukurova region 
and 8.3% in Diyarbakir (Gurbak et al., 2006; Ince et al., 
2003). In Turkey as a whole, Baak et al. found this 
mutation frequency to be 5.4% (Basak, 2008). This muta-
tion was the most frequent one in Iran (33.9%) and 
Kuwait (29.2%); however, it is difficult to explain why this 
mutation is frequent in Diyarbakir, Cukurova and Gaziantep 
as compared to Turkey in general (Table 3) (Baysal et al., 
1992; Boussiou et al., 2008; Kyriacou et al., 2000; 
Darwish et al., 2005; Petkov and Efremov, 2007; Curuk et 
al., 1992; Peykar et al., 2007; Al-Allawi et al., 2006).  
IVS 1.1 (G>A) is the third most frequent mutation in our 
study at 7.7%. It was the second most frequent mutation 
in Cukurova (8.3%) the Aegean (28.2%) and Denizli 
(16.4%) (Curuk et al., 2001; Golesken et al., 2000; Yildiz 
et al., 2005). It was the fourth most frequent (5.5%) 
mutation in Diyarbakir and in Turkey as a whole in accor-
dance with the findings of Baak et al. (2008) and Ince et 
al. (2003). This mutation was seen mainly in the -
thalassemia zone, from Hungary, Yugoslavia, Greece 
and Cyprus to Czechoslovakia (Boussiou et al., 2008; 
Ringelhann et al., 1993; Dimovski et al., 1990; Efremov, 
2007; Indrak et al., 1992). In Turkey, it was common in 
Turkish people originating from Marmara, Aegean and 
Balkans (Basak, 2008).  
Codon 8 (-AA) was the fourth most frequent mutation in 
our study (5.6%) with a ratio that was lower than the 
studies reported from Diyarbakir. In Turkey as a whole, 
Baak et al. reported this mutation as the third most 
frequent with a ratio of 6.1 (Basak, 2008). This mutation 
is most frequent in East Anatolia and the Marmara region 
of Turkey (Basak, 2008). Among the neighboring coun-
tries, it was most frequent in Azerbaijan (21.2%) (Curuk 
et al., 1992). IVS 1.6 (T>C) and -30 (T>A) were the fifth 
most frequent mutation (4.6%) in Gaziantep. Baak et al. 
reported that IVS 1.6 (T>C) mutation was the second 
most frequent one in Turkey as a frequency of 9.5% 
(Basak, 2008).  
The frequency of Codon 39 (C>T) were found in 
Gaziantep, Cukurova and Diyarbakir as 3.6, 6.4 and 
2.8%, respectively (Gurbak et al., 2006; Curuk et al., 
2001). It was the most frequent mutation in Italy 49%, 
Spain 64%, Portugal 33.5%, Bulgaria 21.9% and Tunisia 
49% (Petkov and Efremov, 2007; Ferrara et al., 2001; 
Amselem et al., 1988; Faustino et al., 1999; Fattoum et 
al., 2004). Baak et al. found the average frequency in 
Turkey as a whole to be 3.8% (Basak, 2008). This muta-
tion is usually the most common one that was obseved in 
the West Mediterranean. In contrast, it is rarely seen in 
Cyprus, Lebanon, Iran, Palestine and Azerbaijan (Bozkurt 
et al., 1992; Darwish et al., 2005; Curuk et al., 1992; 
Peykar et al., 2007; Chehab et al., 1987). It has been 
suggested that the distribution pattern of this allele 
correlates with the early migrations of Phoenicians and 
Carthaginians, who spread the -thalassemia allele(s) in 
the Mediterranean Basin (Birgens and Ljung, 2007; 
Cavalli-Sforza et al., 1996). 
This is the first study to determine the frequencies of  
and - thalassemia mutations in the city of Gaziantep. 
When a patient is born with -thalassemia, there is no 
effective treatment option. Therefore, the best method for 
dealing with -thalassemia disease is prenatal diagnosis. 
In the current study, six -thalassemia families who carry 
the -globin gene mutation were given genetic consul-
tation for prenatal diagnosis based  on  DNA  analysis.  In  
 
 




conclusion, after we have identified the most frequent 
mutations in -thalassemia patients living in the city of 
Gaziantep, the frequency of prenatal diagnosis will 
promptly increase. Therefore, this will provide important 
benefits to population health and the national economy 
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